Strides Arcolab has announced receipt of ANDA approval for Labetalol Hydrochloride (HCI) injection, USP, 100 mg per 20 ml and 200 mg per 40 ml, multi-dose vials. This is expected to be launched shortly.
Labetalol is the third product launched under the partnership between Strides and Sagent Pharmaceuticals. Under this partnership, Strides and Sagent are jointly developing, supplying and marketing more than 25 injectable products for the U.S. market.
The company made this announcement during the trading hours today, 09 February 2010.